<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
    
    <title>Vishvas&#39;s notes  | Vaccination</title>
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">

    <meta name="viewport" content="width=device-width,minimum-scale=1">
    <meta name="generator" content="Hugo 0.72.0" />
    
    
      <META NAME="ROBOTS" CONTENT="INDEX, FOLLOW">
    

    <link href="/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/" rel="alternate" type="application/rss+xml" title="Vishvas&#39;s notes" />
    <link href="/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/" rel="feed" type="application/rss+xml" title="Vishvas&#39;s notes" />

    <meta property="og:title" content="Vaccination" />
<meta property="og:description" content="Effectiveness expectations  There are different strains - so vaccination may not be totally effective (just as in case of reinfection). Flare-up possibility: The antibodies the vaccine elicits will have virus neutralizing capabilities and that is what needed. But there are other non neutralizing antibodies that gets produced that can flare up the disease. Called ADE (antibody dependent enhancement) has been observed in Dengue and other viral infections.  Risks    Those who are taking vaccines now may become complacent and not wear masks    The others not vaccinated seeing those getting vaccinated might assume they are protected and not bother    People might just take one shot and drop out for the second    Those vaccinated assume they are protected immediately after the shots which is not true    People would like to wait to get vaccinated." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/" />

<meta itemprop="name" content="Vaccination">
<meta itemprop="description" content="Effectiveness expectations  There are different strains - so vaccination may not be totally effective (just as in case of reinfection). Flare-up possibility: The antibodies the vaccine elicits will have virus neutralizing capabilities and that is what needed. But there are other non neutralizing antibodies that gets produced that can flare up the disease. Called ADE (antibody dependent enhancement) has been observed in Dengue and other viral infections.  Risks    Those who are taking vaccines now may become complacent and not wear masks    The others not vaccinated seeing those getting vaccinated might assume they are protected and not bother    People might just take one shot and drop out for the second    Those vaccinated assume they are protected immediately after the shots which is not true    People would like to wait to get vaccinated.">

<meta itemprop="wordCount" content="1347">



<meta itemprop="keywords" content="" /><meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="Vaccination"/>
<meta name="twitter:description" content="Effectiveness expectations  There are different strains - so vaccination may not be totally effective (just as in case of reinfection). Flare-up possibility: The antibodies the vaccine elicits will have virus neutralizing capabilities and that is what needed. But there are other non neutralizing antibodies that gets produced that can flare up the disease. Called ADE (antibody dependent enhancement) has been observed in Dengue and other viral infections.  Risks    Those who are taking vaccines now may become complacent and not wear masks    The others not vaccinated seeing those getting vaccinated might assume they are protected and not bother    People might just take one shot and drop out for the second    Those vaccinated assume they are protected immediately after the shots which is not true    People would like to wait to get vaccinated."/>

      
    

    <script src="/notes/webpack_dist/dir_tree-bundle.js"></script>
    <script type="text/javascript">
    
    let baseURL = "https:\/\/vvasuki.github.io\/notes\/";
    let basePath = "/" + baseURL.split("/").slice(3).join("/");
    let siteParams = JSON.parse("{\u0022contactlink\u0022:\u0022https:\/\/github.com\/vvasuki\/notes\/issues\/new\u0022,\u0022disqusshortcode\u0022:\u0022vvasuki-site\u0022,\u0022env\u0022:\u0022production\u0022,\u0022githubeditmepathbase\u0022:\u0022https:\/\/github.com\/vvasuki\/notes\/edit\/hugo-source\/content\/\u0022,\u0022mainSections\u0022:[\u0022history\u0022],\u0022mainsections\u0022:[\u0022history\u0022],\u0022math\u0022:true}");
    let pageDefaultsList = JSON.parse("[{\u0022scope\u0022:{\u0022pathPrefix\u0022:\u0022\u0022},\u0022values\u0022:{\u0022comments\u0022:true,\u0022layout\u0022:\u0022page\u0022,\u0022search\u0022:true,\u0022sidebar\u0022:\u0022home_sidebar\u0022}}]");
    let sidebarsData = JSON.parse("{\u0022home_sidebar\u0022:{\u0022contents\u0022:[{\u0022url\u0022:\u0022recdir:\/\/\u0022},{\u0022contents\u0022:[{\u0022title\u0022:\u0022ज्यौतिषम्\u0022,\u0022url\u0022:\u0022..\/jyotiSham\/\u0022},{\u0022title\u0022:\u0022संस्कृतम्\u0022,\u0022url\u0022:\u0022..\/sanskrit\/\u0022},{\u0022title\u0022:\u0022संस्कारः\u0022,\u0022url\u0022:\u0022..\/saMskAra\/\u0022},{\u0022title\u0022:\u0022Notes Home\u0022,\u0022url\u0022:\u0022..\/notes\/\u0022},{\u0022title\u0022:\u0022वेदाः\u0022,\u0022url\u0022:\u0022..\/vedAH\/\u0022},{\u0022title\u0022:\u0022पुराणम्\u0022,\u0022url\u0022:\u0022..\/purANam\/\u0022},{\u0022title\u0022:\u0022काव्यम्\u0022,\u0022url\u0022:\u0022..\/kAvyam\/\u0022},{\u0022title\u0022:\u0022मीमांसा\u0022,\u0022url\u0022:\u0022..\/mImAMsA\/\u0022},{\u0022title\u0022:\u0022त्रिपिटकम्\u0022,\u0022url\u0022:\u0022..\/tipiTaka\/\u0022},{\u0022title\u0022:\u0022पाळयः\u0022,\u0022url\u0022:\u0022..\/pALi\/\u0022},{\u0022title\u0022:\u0022Vishvas\u0027s home page\u0022,\u0022url\u0022:\u0022\/..\/\u0022}],\u0022title\u0022:\u0022सङ्ग्रहान्तरम्\u0022},{\u0022title\u0022:\u0022\\u003ci class=\\\u0022fas fa-hand-holding-heart\\\u0022\\u003e\\u003c\/i\\u003eDonate Via Vishvas\u0022,\u0022url\u0022:\u0022https:\/\/vvasuki.github.io\/interests\/dharma-via-vishvas\/\u0022}],\u0022title\u0022:\u0022Parts\u0022}}");
    let autocompletePageUrl = "\/notes\/data\/pages.tsv";
    
    var pageRelUrlTree = {};
</script>

    <script>
    
    let pageVars = {};
    pageVars.pageUrlMinusBasePath = "\/notes\/biology\/organism\/health\/disease\/contagion\/wuhan_epidemic\/Infection\/vaccination\/".replace(basePath, "/");
    pageVars.pageParams = {};
    pageVars.pageSource = "biology\/organism\/health\/disease\/contagion\/wuhan_epidemic\/Infection\/vaccination.md";
    console.log(pageVars.pageSource);
    var pageDefaults;
    for (let possiblePageDefaults of pageDefaultsList) {
      if (pageVars.pageSource.startsWith(possiblePageDefaults.scope.pathPrefix)) {
        pageDefaults = possiblePageDefaults.values
      }
    }
    
    </script>
    <script src="/notes/webpack_dist/main-bundle.js"></script>
    <script src="/notes/webpack_dist/transliteration-bundle.js"></script>
    <script src="/notes/non_webpack_js/disqus.js"></script>
    <script src="/notes/webpack_dist/ui_lib-bundle.js"></script>
    <link rel="stylesheet" href="/notes/css/fonts.css">
    <link rel="stylesheet" href="/notes/css/@fortawesome/fontawesome-free/css/solid.min.css">
    
    <script type="text/x-mathjax-config">
    MathJax.Hub.Config({"HTML-CSS": { preferredFont: "TeX", availableFonts: ["STIX","TeX"], linebreaks: { automatic:true }, EqnChunk: (MathJax.Hub.Browser.isMobile ? 10 : 50) },
        tex2jax: { inlineMath: [ ["\\$", "\\$"], ["\\(", "\\)"] ], displayMath: [ ["$$","$$"], ["\\[", "\\]"] ], processEscapes: true, ignoreClass: "tex2jax_ignore|dno" },
        TeX: {  noUndefined: { attributes: { mathcolor: "red", mathbackground: "#FFEEEE", mathsize: "90%" } } },
        messageStyle: "none"
    });
</script>
      <script type="text/javascript" id="MathJax-script" async
              src="/notes/non_webpack_js/mathjax/es5/tex-chtml.js?config=TeX-AMS-MML_HTMLorMML">
      </script>
    

    <link rel="stylesheet" href="/notes/css/@fortawesome/fontawesome-free/css/fontawesome.min.css">

    
    <link rel="alternate" hreflang="sa-Deva" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/" />
    <link rel="alternate" hreflang="sa-Deva" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=devanagari" />
    <link rel="alternate" hreflang="sa-Knda" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=kannada" />
    <link rel="alternate" hreflang="sa-Mlym" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=malayalam" />
    <link rel="alternate" hreflang="sa-Telu" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=telugu" />
    <link rel="alternate" hreflang="sa-Taml-t-sa-Taml-m0-superscript" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=tamil_superscripted" />
    <link rel="alternate" hreflang="sa-Taml" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=tamil" />
    <link rel="alternate" hreflang="sa-Gran" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=grantha" />
    <link rel="alternate" hreflang="sa-Gujr" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=gujarati" />
    <link rel="alternate" hreflang="sa-Orya" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=oriya" />
    <link rel="alternate" hreflang="sa-Beng-t-sa-Beng-m0-assamese" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=assamese" />
    <link rel="alternate" hreflang="sa-Beng" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=bengali" />
    <link rel="alternate" hreflang="sa-Guru" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=gurmukhi" />
    <link rel="alternate" hreflang="sa-Cyrl" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=cyrillic" />
    <link rel="alternate" hreflang="sa-Sinh" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=sinhala" />
    <link rel="alternate" hreflang="sa-Shar" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=sharada" />
    <link rel="alternate" hreflang="sa-Brah" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=brahmi" />
    <link rel="alternate" hreflang="sa-Modi" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=modi" />
    <link rel="alternate" hreflang="sa-Tirh" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=tirhuta_maithili" />
    <link rel="alternate" hreflang="sa-Latn-t-sa-Zyyy-m0-iast" href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/?transliteration_target=iast" />
  </head>

  <body class="ma0 bg-near-white">
    
\(
% groupings of objects.
\newcommand{\set}[1]{\left\{ #1 \right\}}
\newcommand{\seq}[1]{\left(#1\right)}
\newcommand{\ang}[1]{\langle#1\rangle}
\newcommand{\tuple}[1]{\left(#1\right)}
\newcommand{\size}[1]{\left| #1\right|}

\newcommand{\comp}{\circ}


% numerical shortcuts.
\newcommand{\abs}[1]{\left| #1\right|}
\newcommand{\floor}[1]{\left\lfloor #1 \right\rfloor}
\newcommand{\ceil}[1]{\left\lceil #1 \right\rceil}

% linear algebra shortcuts.
\newcommand{\change}{\Delta}
\newcommand{\norm}[1]{\left\| #1\right\|}
\newcommand{\dprod}[1]{\langle#1\rangle}
\newcommand{\linspan}[1]{\langle#1\rangle}
\newcommand{\conj}[1]{\overline{#1}}
\newcommand{\der}[1]{\frac{d#1}{dx}}
\newcommand{\lap}{\Delta}
\newcommand{\kron}{\otimes}
\newcommand{\nperp}{\nvdash}

\newcommand{\mat}[1]{\left[ \begin{smallmatrix}#1 \end{smallmatrix} \right]}

% derivatives and limits
\newcommand{\partder}[2]{\frac{\partial #1}{\partial #2}}
\newcommand{\partdern}[3]{\frac{\partial^{#3 #1}}{\partial #2^{#3}}}
\newcommand{\gradient}{\nabla}
\newcommand{\subdifferential}{\partial}

% Arrows
\newcommand{\diverge}{\nearrow}
\newcommand{\notto}{\nrightarrow}
\newcommand{\up}{\uparrow}
\newcommand{\down}{\downarrow}
% gets and gives are defined!

% ordering operators
\newcommand{\oleq}{\preceq}
\newcommand{\ogeq}{\succeq}

% programming and logic operators
\newcommand{\dfn}{:=}
\newcommand{\assign}{:=}
\newcommand{\co}{\ co\ }
\newcommand{\en}{\ en\ }


% logic operators
\newcommand{\xor}{\oplus}
\newcommand{\Land}{\bigwedge}
\newcommand{\Lor}{\bigvee}
\newcommand{\finish}{\Box}
\newcommand{\contra}{\Rightarrow \Leftarrow}
\newcommand{\iseq}{\stackrel{_?{=}}}


% Set theory
\newcommand{\symdiff}{\Delta}
\newcommand{\setdiff}{\backslash}
\newcommand{\union}{\cup}
\newcommand{\inters}{\cap}
\newcommand{\Union}{\bigcup}
\newcommand{\Inters}{\bigcap}
\newcommand{\nullSet}{\phi}


% graph theory
\newcommand{\nbd}{\Gamma}

% Script alphabets
% For reals, use \Re

% greek letters
\newcommand{\eps}{\epsilon}
\newcommand{\del}{\delta}
\newcommand{\ga}{\alpha}
\newcommand{\gb}{\beta}
\newcommand{\gd}{\del}
\newcommand{\gp}{\pi}
\newcommand{\gf}{\phi}
\newcommand{\gh}{\eta}
\newcommand{\gF}{\Phi}
\newcommand{\gl}{\lambda}
\newcommand{\gm}{\mu}
\newcommand{\gn}{\nu}
\newcommand{\gr}{\rho}
\newcommand{\gs}{\sigma}
\newcommand{\gth}{\theta}
\newcommand{\gx}{\xi}

\newcommand{\sw}{\sigma}
\newcommand{\SW}{\Sigma}
\newcommand{\ew}{\lambda}
\newcommand{\EW}{\Lambda}

\newcommand{\Del}{\Delta}
\newcommand{\gD}{\Delta}
\newcommand{\gG}{\Gamma}
\newcommand{\gO}{\Omega}
\newcommand{\gS}{\Sigma}
\newcommand{\gTh}{\Theta}

% Bold english letters.
\newcommand{\bA}{\mathbf{A}}
\newcommand{\bB}{\mathbf{B}}
\newcommand{\bC}{\mathbf{C}}
\newcommand{\bD}{\mathbf{D}}
\newcommand{\bE}{\mathbf{E}}
\newcommand{\bF}{\mathbf{F}}
\newcommand{\bG}{\mathbf{G}}
\newcommand{\bH}{\mathbf{H}}
\newcommand{\bI}{\mathbf{I}}
\newcommand{\bJ}{\mathbf{J}}
\newcommand{\bK}{\mathbf{K}}
\newcommand{\bL}{\mathbf{L}}
\newcommand{\bM}{\mathbf{M}}
\newcommand{\bN}{\mathbf{N}}
\newcommand{\bO}{\mathbf{O}}
\newcommand{\bP}{\mathbf{P}}
\newcommand{\bQ}{\mathbf{Q}}
\newcommand{\bR}{\mathbf{R}}
\newcommand{\bS}{\mathbf{S}}
\newcommand{\bT}{\mathbf{T}}
\newcommand{\bU}{\mathbf{U}}
\newcommand{\bV}{\mathbf{V}}
\newcommand{\bW}{\mathbf{W}}
\newcommand{\bX}{\mathbf{X}}
\newcommand{\bY}{\mathbf{Y}}
\newcommand{\bZ}{\mathbf{Z}}

\newcommand{\bba}{\mathbf{a}}
\newcommand{\bbb}{\mathbf{b}}
\newcommand{\bbc}{\mathbf{c}}
\newcommand{\bbd}{\mathbf{d}}
\newcommand{\bbe}{\mathbf{e}}
\newcommand{\bbf}{\mathbf{f}}
\newcommand{\bbg}{\mathbf{g}}
\newcommand{\bbh}{\mathbf{h}}
\newcommand{\bbk}{\mathbf{k}}
\newcommand{\bbl}{\mathbf{l}}
\newcommand{\bbm}{\mathbf{m}}
\newcommand{\bbn}{\mathbf{n}}
\newcommand{\bbp}{\mathbf{p}}
\newcommand{\bbq}{\mathbf{q}}
\newcommand{\bbr}{\mathbf{r}}
\newcommand{\bbs}{\mathbf{s}}
\newcommand{\bbt}{\mathbf{t}}
\newcommand{\bbu}{\mathbf{u}}
\newcommand{\bbv}{\mathbf{v}}
\newcommand{\bbw}{\mathbf{w}}
\newcommand{\bbx}{\mathbf{x}}
\newcommand{\bby}{\mathbf{y}}
\newcommand{\bbz}{\mathbf{z}}
\newcommand{\0}{\mathbf{0}}
\newcommand{\1}{\mathbf{1}}

% Caligraphic english alphabet
\newcommand{\cA}{\mathcal{A}}
\newcommand{\cB}{\mathcal{B}}
\newcommand{\cC}{\mathcal{C}}
\newcommand{\cD}{\mathcal{D}}
\newcommand{\cE}{\mathcal{E}}
\newcommand{\cF}{\mathcal{F}}
\newcommand{\cG}{\mathcal{G}}
\newcommand{\cH}{\mathcal{H}}
\newcommand{\cI}{\mathcal{I}}
\newcommand{\cJ}{\mathcal{J}}
\newcommand{\cK}{\mathcal{K}}
\newcommand{\cL}{\mathcal{L}}
\newcommand{\cM}{\mathcal{M}}
\newcommand{\cN}{\mathcal{N}}
\newcommand{\cO}{\mathcal{O}}
\newcommand{\cP}{\mathcal{P}}
\newcommand{\cQ}{\mathcal{Q}}
\newcommand{\cR}{\mathcal{R}}
\newcommand{\cS}{\mathcal{S}}
\newcommand{\cT}{\mathcal{T}}
\newcommand{\cU}{\mathcal{U}}
\newcommand{\cV}{\mathcal{V}}
\newcommand{\cW}{\mathcal{W}}
\newcommand{\cX}{\mathcal{X}}
\newcommand{\cY}{\mathcal{Y}}
\newcommand{\cZ}{\mathcal{Z}}


% Formatting shortcuts
\newcommand{\red}[1]{\textcolor{red}{#1}}
\newcommand{\blue}[1]{\textcolor{blue}{#1}}
\newcommand{\htext}[2]{\texorpdfstring{#1}{#2}}

% Statistics
\newcommand{\distr}{\sim}
\newcommand{\stddev}{\sigma}
\newcommand{\covmatrix}{\Sigma}
\newcommand{\mean}{\mu}
\newcommand{\param}{\theta}
\newcommand{\gthEst}{\hat{\theta}}
\newcommand{\ftr}{\phi}
\newcommand{\est}[1]{\hat{#1}}

% General utility
\newcommand{\todo}[1]{\textbf{[TODO]}] \footnote{TODO: #1}}
\newcommand{\tbc}{[\textbf{Incomplete}]}
\newcommand{\chk}{[\textbf{Check}]}
\newcommand{\why}{[\textbf{Find proof}]}
\newcommand{\opt}[1]{\textit{#1}}

\newcommand{\experience}[1]{[\textbf{Personal Experience}]: #1 \blacktriangle}
\newcommand{\pf}[1]{[\textbf{Proof}]: #1 \Box}
\newcommand{\core}[1]{\textbf{Core Idea}: #1 \Arrowvert}
\newcommand{\example}[1]{\textbf{Example}: #1 \blacktriangle}
\newcommand{\error}[1]{\textbf{Error alert}: #1 \triangle}
\newcommand{\oprob}{[\textbf{OP}]: }


\renewcommand{\~}{\htext{$\sim$}{~}}

\DeclareMathOperator*{\argmin}{arg\,min}
\DeclareMathOperator*{\argmax}{arg\,max}


\)



    
<header class="p-1 bg-yellow">
    <nav role="navigation">
      <div id="div_top_bar" class="row">
        <div class="col-md-3 justify-content-start">
          <a  href="/notes/" class="btn col border">
            <i class="fas fa-gopuram ">Vishvas&#39;s notes <br/> Vaccination</i>
          </a>
        </div>
        <div id="div_top_bar_right" class="col-md-auto d-flex justify-content-center">
          <form action="/notes/search">
            <input id="titleSearchInputBox" placeholder="शीर्षिकान्विष्यताम्" name="s"><i class="btn fas fa-search "></i>
          </form>
          <a href="/notes/custom_site_search/"  class="btn btn-default">Full search</a>
          <select name="transliterationDropdown" size="1" onchange="module_transliteration.updateTransliteration()">
            <option value="devanagari" selected="">स</option>
            <option value="iast">ā</option>
            <option value="kannada">ಅ</option>
            <option value="malayalam">അ</option>
            <option value="telugu">క</option>
            <option value="tamil_superscripted">க²</option>
            <option value="tamil_extended">க</option>
            <option value="grantha">𑌅</option>
            <option value="gujarati">અ</option>
            <option value="oriya">ଅ</option>
            <option value="assamese">অস</option>
            <option value="bengali">অ</option>
            <option value="gurmukhi">ਅ</option>
            <option value="cyrillic">пу</option>
            <option value="sinhala">අ</option>
            <option value="sharada">𑆑𑇀𑆰</option>
            <option value="brahmi">𑀅</option>
            <option value="modi">𑘦𑘻𑘚𑘲</option>
            <option value="tirhuta_maithili">𑒁</option>
          </select>
        </div>
        <div class="row col  d-flex justify-content-center">
          <div><a  name="previousPage" href="" class="btn btn-secondary">###<i class="fas fa-caret-left"></i></a></div>
          <div ><a name="nextPage" href="" class="btn btn-secondary"><i class="fas fa-caret-right"></i> ### </a></div>
        </div>
        <ul id="top-bar-right-custom" class="list-group list-group-horizontal">
        </ul>
      </div>
    </nav>
</header>

    
    <div class="row" name="contentRow">
      
      <aside class="col-md-3 card border " id="sidebar">
        <div id="sidebarTitle" class="card-title bg-light-gray border d-flex justify-content-between" >
          <a name="sidebarToggleLink" data-toggle="collapse" href="#sidebar_body" role="button" aria-expanded="true" aria-controls="sidebar_body" onclick="module_main.default.sidebarToggleHandler()">
            Menu <i class="fas fa-caret-down"></i></a>
        </div>
        <nav class="card-body p-0 collapse show" id="sidebar_body">
          <ul id="displayed_sidebar" class="list pl2 p-2 bg-yellow">
        </ul>
        </nav>
      </aside>
      <main class="col p-3" role="main">
        
<header class='border d-flex justify-content-between'>
    <h1 id="Vaccination">Vaccination</h1>
    
    <a id="editLink" class="btn btn-primary"  href="https://github.com/vvasuki/notes/edit/hugo-source/content/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination.md"><i class="fas fa-edit"></i></a>
    
</header>
<article>
  <aside id="toc_card" class="card border ">
    <div id="toc_header" class="card-title border d-flex justify-content-between">
        <a data-toggle="collapse" href="#toc_body" role="button" aria-expanded="true" aria-controls="toc_body">
          What's in this page? <i class="fas fa-caret-down"></i> </a>
    </div>
    <div id="toc_body" class="card-body collapse p-0">
      
      <ul id="toc_ul" class="list p-0">
      </ul>
    </div>
  </aside>
  <div id="post_content">
  <h2 id="effectiveness-expectations">Effectiveness expectations</h2>
<ul>
<li>There are different strains - so vaccination may not be totally effective (just as in case of reinfection).</li>
<li>Flare-up possibility: The antibodies the vaccine elicits will have virus neutralizing capabilities and that is what needed. But there are other non neutralizing antibodies that gets produced that can flare up the disease. Called ADE (antibody dependent enhancement) has been observed in Dengue and other viral infections.</li>
</ul>
<h3 id="risks">Risks</h3>
<ul>
<li>
<ol>
<li>Those who are taking vaccines now may become complacent and not wear masks</li>
</ol>
</li>
<li>
<ol start="2">
<li>The others not vaccinated seeing those getting vaccinated might assume they are protected and not bother</li>
</ol>
</li>
<li>
<ol start="3">
<li>People might just take one shot and drop out for the second</li>
</ol>
</li>
<li>
<ol start="4">
<li>Those vaccinated assume they are protected immediately after the shots which is not true</li>
</ol>
</li>
<li>
<ol start="5">
<li>People would like to wait to get vaccinated.</li>
</ol>
</li>
</ul>
<h2 id="effectiveness-duration">Effectiveness duration</h2>
<ul>
<li>T cell response following even mild and asymptomatic infection can last upto 6 months. See reinfection page for details.</li>
<li>What the duration of immunity is for a given COVID-19 vaccine will only be resolved once community-wide vaccination programmes progress. Phase 3 trials will tell us about efficacy and safety, but well designed phase 4 trials are essential based on representative and large numbers of those vaccinated and follow up over time.</li>
</ul>
<h2 id="approaches">Approaches</h2>
<h3 id="mrna-for-spike-protein">mRNA for spike protein</h3>
<ul>
<li>COVID-19 mRNA vaccines give instructions for our cells to make “spike protein”, which gets desposited on cell surface. Then, an immune response to them devolops.</li>
</ul>
<h3 id="spike-protein-injection">Spike protein injection</h3>
<p>Trigger antibody development thence.</p>
<h3 id="foiling-spike-protein">Foiling Spike protein</h3>
<ul>
<li>Idea is to bind and block S proteins.</li>
</ul>
<h4 id="ace2-decoys">ACE2 decoys</h4>
<ul>
<li>Entry of the virus which happens through binding of Spike (S) protein of the virus with ACE2 receptors found in the lungs. If you use decoy ACE2 substance (which bind better),the virus might bind to this synthetic ACE2 rather than original ACE2 receptors resulting in less viruses thus reducing the inflammation in the lungs. The main problem is the short half life of this synthetic ACE2. Scientists are working how to increase the half life.</li>
</ul>
<h3 id="inactivated-viral-vaccines">Inactivated viral vaccines</h3>
<ul>
<li>Hepatitis A and Salk Polio virus are inactivated vaccines. These vaccines have adjuvants with alum or aluminium that can cause severe reactions at injection site as opposed to mRNA or DNA vaccines.</li>
<li>Dr Kang expresses reservations if the inactivated vaccines like COVAXIN work with new mutants as the mutations are occurring at the spike of the virus.</li>
</ul>
<h2 id="natural-infection">Natural infection</h2>
<ul>
<li>See <a href="../reinfection">reinfection</a> page.</li>
</ul>
<h2 id="oxford-astra-zeneca-chad0x1-vaccine-azd1222">Oxford Astra-Zeneca ChAd0x1 vaccine azd1222</h2>
<ul>
<li>Aka Covishield by SII in India.</li>
<li>It is chimpanzee adenovirus packaged with viral Spike protein instruction DNA, due to which the body produces spike proteins and thence antibodies to those.</li>
<li>safely stored at temperatures of 2C to 8C, about the same as a domestic fridge</li>
</ul>
<h3 id="efficacy">Efficacy</h3>
<ul>
<li>Indian population: Efficacy with single dose 52%. Second dose close to 12 weeks 78.79%</li>
<li>UK Population: The efficacy with the first dose is about 70%. UK govt is going for single shot followed by 2nd dose by 12 weeks (will supposedly make efficacy 80%).
<ul>
<li>vaccine efficacy was 62.1% (n=8,895; CI 41.0% to 75.7%), and 90.0% (n=2,741; CI 67.4% to 97.0%) in participants who received a half dose followed by a full dose.</li>
<li>The protection starts on the 22nd day after the first dose.</li>
</ul>
</li>
<li>if you have antibodies to the vector that they use, Chimpanzee Adenovirus results in neutralizing the vaccine efficacy. Such antibodies may develop after the first dose as well, nullifying the second dose. (Chinese had tried similar trials and had demonstrated 52% of their participants had antibodies to Adenovirus which is a naturally occurring viral infection.)</li>
<li>It reduces both asymptomatic ones as well as Severe cases.</li>
<li>South Africa has stalled the Oxford vaccine as the reports emerged the vaccine is not effective with mild to moderate cases with B1351 variant from South Africa.</li>
</ul>
<h3 id="uk-trial-problems">UK Trial problems</h3>
<ul>
<li>Less Black  and Asian representation.</li>
<li>Less data about 65 plus age group. Only 5.9% were above age 65. Antibody titre levels were less in those &gt;65 years. The lowered antibody response was because the 2nd dose was given &lt;6 weeks.</li>
</ul>
<h3 id="severe-adverse-reactions">Severe Adverse reactions</h3>
<ul>
<li>Side effects wise, relatively more side effects (fever, pain etc) reported compared to mRNA vaccines.</li>
<li>Oxford Vaccine caused 1 transverse myelitis (inflammation of the spinal cord)  in a volunteer</li>
</ul>
<h2 id="pfizer-biontech">Pfizer-BioNTech</h2>
<ul>
<li>An mRNA vaccine</li>
<li>Storage requirement at -70 C</li>
</ul>
<h3 id="efficacy-1">Efficacy</h3>
<ul>
<li>50% protection after 14 days of first shot.</li>
<li>Single shot of Pfizer vaccine is 85% effective in  preventing symptomatic disease 15-28 days after the 1st dose: Israel data.</li>
<li>Reduces mild/ severe cases by 95% 7 days after 2nd dose of vaccine; reduces infection by 90%.</li>
<li>Immune response after mRNA vaccinations after 2 doses demonstrated good and safe antibodies 8 weeks later. The efficacy against mutants was slightly reduced.</li>
</ul>
<h3 id="severe-adverse-reactions-1">Severe Adverse reactions</h3>
<ul>
<li>The exclusion criteria that was used during Pfizer vaccine trial included people with allergies. Bang on, on the field, exactly same happened. 2 healthcare professionals in the UK had anaphylactic reaction. Now the health regulators have adviced those having similar allergies or anaphylaxis should not get this vaccine.</li>
<li>Pfizer vaccine volunteers got Bell&rsquo;s palsy(4 of them)</li>
<li>Low platelet count called Immune thrombocytopenia following Pfizer/Moderna vaccine administration are getting reported in the USA in small numbers.</li>
<li>Till date,66 cases out of ~18 million vaccinations (=0.00000003%) had such reactions. All but 1 within 11 minutes. No deaths at all.</li>
</ul>
<h2 id="moderna-vaccine">Moderna vaccine</h2>
<ul>
<li>Synthetic mRNA-1273 for spike protein.</li>
<li>Storage: -20 Deg up to 6 months</li>
</ul>
<h3 id="efficacy-2">Efficacy</h3>
<ul>
<li>94.1% efficacy.</li>
<li>Shown effective about 40 days after injection.</li>
<li>It is not doing much to reduce the asymptomatic ones. The mRNA vaccines give good robust antibodies but not the IgA antibodies coating the nasal passages.So,you still carry viruses and keep spreading.</li>
</ul>
<h2 id="novavax-covovax-vaccine">Novavax/ Covovax vaccine</h2>
<ul>
<li>Directly injects stabilized spike proteins (mRNA or DNA not used.) This same technology has been used since 1986 with Hep B vaccines that are given to even infants and found extremely safer.</li>
<li>Serum Institute in India tied up with Novavax and ready to roll out vaccines by July.</li>
<li>Efficacy: Overall - 89%, South Africa - 50%
<ul>
<li>Current strain D614G: 95%
UK strain B1.1.7: 89.3%
South African  variant 501Y.V2: 60%
HIV Neg: 60.1%
HIV Pos: 49.4%
Severe disease: 100%</li>
</ul>
</li>
<li>Among placebo group for Novavax’s vaccine in South Africa, people with prior #COVID19 infections appeared just as likely to get sick as people without prior infections—means past infection wasn’t fully protective for B1351 variant.</li>
</ul>
<h2 id="bharat-biotech-covaxin-bbv152">Bharat Biotech Covaxin BBV152</h2>
<ul>
<li>inactivated / attenuated whole virus particles</li>
<li>DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India.</li>
</ul>
<h3 id="severe-adverse-reactions-2">Severe Adverse reactions</h3>
<ul>
<li>1 person developed encephalitis. Was threatened with a lawsuit.</li>
</ul>
<h2 id="gamelaya-sputnik-v">Gamelaya Sputnik V</h2>
<ul>
<li>The Russians have used human (rather than chimp) Adenovirus and use 2 different strains (Ad26 and Ad5) as vectors cleverly in their Sputnik vaccine. Apparently,this reduces the chances of preexisting antibodies reducing the efficacy.</li>
<li>Russia says its Sputnik V vaccine is 91% effective.</li>
<li>Storage: Regular fridge temperature.</li>
</ul>
<h2 id="sinovac-coronavac">Sinovac CoronaVac</h2>
<ul>
<li>inactivated / attenuated whole virus particles</li>
<li>Brazil: 50.38% effective in late-stage trials in Brazil (far below the 78% previously announced)</li>
<li>Indonesian drug regulators say interim data from Phase 3 trials showed it is 65.3% effective</li>
<li>stored in a standard refrigerator at 2-8 degrees Celsius</li>
</ul>
<h2 id="sinopharm-vaccine">Sinopharm vaccine</h2>
<ul>
<li>inactivated / attenuated whole virus particles</li>
<li>Supposedly 79.34% effective. UAE: 86% effective</li>
</ul>
<h2 id="johnson-and-johnson-jnj-janssen-vaccine">Johnson and Johnson (JNJ Janssen) vaccine</h2>
<ul>
<li>uses Ad26 Adenovirus as a vector carrying the virus spike protein.</li>
<li>single dose vaccine.</li>
<li>Efficacy
<ul>
<li>Overall - 66%, South Africa: 57%</li>
<li>66 % effective in Latin America, 57 % effective in South Africa.</li>
<li>85 % effective overall at preventing severe disease</li>
</ul>
</li>
</ul>
<h2 id="other-trials-as-of-2020-12">Other Trials as of 2020-12</h2>
<ul>
<li>FDA standards - &ldquo;If a particular vaccine doesn&rsquo;t demonstrate a minimum of 50 percent efficacy, it will not be approved.&rdquo;</li>
</ul>
<h2 id="failed-attempts">Failed attempts</h2>
<ul>
<li>BCG vaccination effect.</li>
</ul>
<h2 id="india">India</h2>
<h3 id="approvals">Approvals</h3>
<ul>
<li>Oxford/ AstraZeneca. manufactured locally by the Serum Institute of India.</li>
<li>Bharat Biotech - approved &ldquo;in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains&rdquo;.</li>
</ul>
<h3 id="immunization-priority">Immunization priority</h3>
<p>60% of vaccines globally, plans to immunise about 300 million people by July 2021. It will prioritise health care workers, the emergency services, and those who are clinically vulnerable because of age or pre-existing conditions.</p>

  </div>
</article>







<aside class="card border" id="section-tree-item-">
    <div class="card-title bg-light-gray border d-flex justify-content-between">
        <a href="https://vvasuki.github.io/notes/biology/organism/health/disease/contagion/wuhan_epidemic/Infection/vaccination/">Vaccination </a>
        <a data-toggle="collapse" href="#section-tree-item-body-" role="button" aria-expanded="false" aria-controls="section-tree-item-body-" >…<i class="fas fa-caret-down" class="collapsed"></i> </a>
    </div>
    <nav id="section-tree-item-body-" class="card-body p-0 collapse">
        
        <li>draft: false</li>
        
        <li>iscjklanguage: false</li>
        
        <li>title: Vaccination</li>
        
    </nav>
</aside>


      </main>
    </div>
    <footer class="bg-yellow  p-1" role="contentinfo">
  <div id="disqus_thread"></div>
  <div id="div_footer_bar" class="container-fluid d-flex justify-content-between">
    <a class="btn btn-secondary" href="https://github.com/vvasuki/notes/issues/new" >
      प्रतिस्पन्दः
    </a>
    <a class="btn btn-secondary" href="http://creativecommons.org/licenses/by/4.0/"><img alt="Creative Commons License" style="border-width:0" src="https://i.creativecommons.org/l/by/4.0/80x15.png" /></a>
    <div class="btn small border">
      Built on 2021 Mar 7 16:22:41 UTC. (<a href="http://google.com/search?q=16%3a22%3a41%20UTC to IST">IST</a>)
    </div>
  <ul id="footer-bar-right-custom" class="list-group list-group-horizontal">
  </ul>
  </div>
</footer>

  </body>
  <script type='text/javascript'>
    
    
    
    module_main.default.onDocumentReadyTasks();
  </script>
</html>
